Business
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 Cash and cash equivalents of $101M as of March 31, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clini
About this update from Kalaris Therapeutics, Inc.
[{"type":"image","alt":"Kalaris Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kalaris Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/977835051d0e4fa1cb742bd1798bc7e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HZjBrGjL._tUyizJOxV6og--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/977835051d0e4fa1cb742bd1798bc7e3","width":140,"height":40}},"lazy":false},{"type":"text","content":"Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 ","length":287,"tagName":"p"},{"type":"text","content":"Cash and cash equivalents of $101M as of March 31, 2025, expected to fund operations into Q4 2026","length":97,"tagName":"p"},{"type":"text","content":"PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, today announced financial results for the first quarter ended March 31, 2025 and provided a business update.","length":361,"tagName":"p"},{"type":"text","content":"“We are excited by our progress in 2025,” said Andrew Oxtoby, Chief Executive Officer of Kalaris. “We recently completed our merger with Allovir, and our Phase 1 trial investigating TH103 for nAMD is well underway. TH103 was engineered by VEGF pioneer, Napoleone Ferrara, MD, to address the limitations of current nAMD therapies and has demonstrated both potent anti-VEGF activity and sustained ocular residence time in preclinical studies. TH103 has the potential to provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina. We look forward to reporting the initial clinical data from our Phase 1 trial in the fourth quarter of this year.”","length":697,"tagName":"p"},{"type":"text","content":"Business Highlights ","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Kalaris is currently enrolling a Phase 1, single a...